Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
HOXA11
REST API REST API
Homo sapiens
HOXA11 is differentially expressed in 242 experiments: 139 organism parts: prostate, uterus, ... (137 more);, 186 disease states: normal, acute promyelocytic leukemia, ... (184 more);, 88 cell types 408 cell lines 19 compound treatments and 65 other conditions.
Synonyms HOX1, HOX1I
Orthologs hoxa11a (Danio rerio)   RGD1566402 (Rattus norvegicus)   hoxa11b (Danio rerio)   E1BNP2_BOVIN (Bos taurus)   Hoxa11 (Mus musculus)   HXA11_CHICK (Gallus gallus)   hoxa11 (Xenopus laevis)   HOXA11 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein binding, regulation of transcription, DNA-dependent, protein complex, developmental growth, mesodermal cell fate specification, proximal/distal pattern formation, sequence-specific DNA binding, anatomical structure morphogenesis, multicellular organismal development, nucleus, transcription factor complex, positive regulation of transcription, DNA-dependent, dorsal/ventral pattern formation, branching involved in ureteric bud morphogenesis, positive regulation of chondrocyte differentiation, protein-DNA complex, positive regulation of cell development, metanephros development, embryonic digit morphogenesis, skeletal system development, cartilage development involved in endochondral bone morphogenesis, embryonic limb morphogenesis, sequence-specific DNA binding transcription factor activity, organ induction, anterior/posterior pattern specification
InterPro Term Homeobox, Homeobox_eu, DUF3528
UniProt Accession P31270
Gene-Disease Assocation RADIOULNAR SYNOSTOSIS WITH AMEGAKARYOCYTIC THROMBOCYTOPENIA
Search EB-eye ENSG00000005073
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, ... (26 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, ... (40 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-20081, E-GEOD-5823, E-GEOD-19639
SW480
3
E-MEXP-1014, E-MTAB-37, E-GEOD-18005
AGS
2
E-GEOD-15460, E-MTAB-37
DU145
2
E-GEOD-17482, E-GEOD-20089
MOLT4
2
E-MTAB-62, E-MTAB-37
T84
2
E-MTAB-37, E-GEOD-1474
402 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-19397, E-GEOD-3920, E-MEXP-750, ... (46 experiments)

Factor Value U/D Experiments
hematopoietic stem cell
2
E-MEXP-1403, E-MEXP-872
human embryonic stem cell
1
2
E-GEOD-20033, E-GEOD-18265, E-GEOD-18147
fibroblast
1
2
E-GEOD-3920, E-GEOD-3204, E-MEXP-466
nucleus pulposus
1
E-MEXP-2488
wild_type
1
E-GEOD-20193
adipose tissue-derived stem cell
1
E-MEXP-872
82 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-1869, E-GEOD-2466, E-GEOD-16363, ... (46 experiments)

Factor Value U/D Experiments
acute lymphoblastic leukemia
3
E-MTAB-37, E-MTAB-62, E-GEOD-96
colon carcinoma
3
E-MTAB-37, E-GEOD-3726, E-MTAB-62
lung adenocarcinoma
3
E-MTAB-62, E-MTAB-37, E-MEXP-231
sarcoma
2
E-GEOD-2719, E-MTAB-62
Burkitt's lymphoma
2
E-MTAB-37, E-GEOD-96
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
180 more value(s).


Compound treatment

studied in E-GEOD-1417, E-GEOD-5824, E-TABM-868, E-MEXP-941, E-GEOD-5339, ... (14 experiments)

Factor Value U/D Experiments
none
2
4
E-GEOD-412, E-GEOD-1417, E-GEOD-5824, E-TABM-868, E-GEOD-7307, ... (6 experiments)
glutamine
2
E-MEXP-1335, E-MEXP-941
17beta-estradiol
5
1
E-GEOD-4006
glucose
1
E-MEXP-941
vitamin E
1
E-MEXP-1327
lipopolysaccharide
1
E-TABM-868
13 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
28
2
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37, E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19519

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-GEOD-1729

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-2171, E-GEOD-21589, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-MEXP-1251, ... (10 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-GEOD-2666, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-TABM-147, E-GEOD-21138

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-20847, E-GEOD-6431, E-MEXP-2340, ... (6 experiments)

Genotype
studied in E-MEXP-149, E-GEOD-2466, E-MEXP-421, E-TABM-321, E-TABM-868, ... (8 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-13073, E-GEOD-5681, E-GEOD-20504, E-MEXP-1446, ... (9 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-TABM-325, E-MEXP-1956, E-MEXP-2069, E-GEOD-1926, E-GEOD-19519, ... (23 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108, E-GEOD-980, E-GEOD-17400

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-22056, E-GEOD-12662

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-21750, E-GEOD-17636

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19246, E-GEOD-1343

Replicate
studied in E-GEOD-10797, E-GEOD-10896

RNAi
studied in E-GEOD-3697, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Treatment
studied in E-GEOD-16837, E-GEOD-19246, E-GEOD-15799

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290

Processing time: 0.599 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM